| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
PROCEPT BioRobotics Corporation$20.89
+1.14 (+5.77%)
D 31Pipeline Score MedTech · Commercial
Market Cap
1.65 B
EPS
-1.83
P/E Ratio
-
Value Trade
19.27 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
83.13 M
R&D Expenses
21.46 M
Operating CF
-38.13 M
Total Assets
487.06 M
Total Liabilities
139.40 M
Equity
347.67 M
D/E Ratio
12,345
10.52 %
Week
16.14 %
1 Month
8.98 %
3 Month
3.5 %
6 Month
-17.14 %
5 Year
-17.14 %
All Time
Cash Data
Cash Position
245.64 M
Monthly Burn
12.71 M
Runway
17.2 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
1.23 M
52 Week Range
19.35 - 66.85
% held by Insiders
4.05 %
% held by Institutions
100.21 %
Enterprise Value
1.48 B
Total Shares
56.94 M
Short %
13.94 %
Float Shares
52.90 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D31
Pipeline Score $246M
Pipeline ValueValuation Signal
1
Drugs Scored0.2x
rNPV / MCap Top 38%
Micro Cap (rank 566 of 911)
Percentile RankPROCEPT BioRobotics Corporation faces pipeline headwinds (31/100), with $673M risk-adjusted pipeline value, led by PRO 2000 in HIV Infections (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRO 2000 Small molecule | HIV Infections | Phase 1 | NCT00006207 | 12% | $673M | COMPLETED | 60 | - | - | — | - | Jul 30, 2008 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PRCT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PRCT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PRCTPROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval
PROCEPT BioRobotics has completed enrollment in its WATER IV study, which evaluates Aquablation therapy against radical prostatectomy. The company also received FDA IDE approval for a second study comparing Aquablation therapy to active surveillance. Both studies aim to assess long-term outcomes for prostate cancer patients, with results expected to be presented at the AUA Annual Meeting in 2027.
Read more →PRCT▲ +10.7%on this news
PROCEPT BioRobotics to Attend Three Upcoming Investor Conferences in May & June
PROCEPT BioRobotics will participate in three investor conferences scheduled throughout May and June 2026. The events include the Bank of America Health Care Conference in Las Vegas, the 46th Annual William Blair Growth Stock Conference in Chicago, and the Truist Med-Tech Conference in Boston. These presentations aim to showcase the company’s advancements in surgical robotics and its focus on urological care. Webcasts of the events will be available for replay on the company's website for 90 days post-event.
Read more →PRCT▼ -5.7%on this newsshared move
PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
PROCEPT BioRobotics reported its first quarter 2026 financial results, showcasing a revenue growth of 20% to $83.1 million, largely due to increased U.S. system sales. The company noted a significant rise in U.S. procedures, completing approximately 12,200, marking a 30% increase from the previous year. However, operating expenses also rose, which contributed to a net loss of $31.6 million. The company has received FDA clearance for its enhanced FirstAssist AI software aimed at improving Aquablation therapy. Looking ahead, PROCEPT BioRobotics anticipates continued growth for the full year 2026, projecting revenues between $390 million to $410 million.
Read more →PRCTPROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026
PROCEPT BioRobotics will announce its financial results for Q1 2026 on April 29, 2026. The company specializes in surgical robotics aimed at improving urological patient care. A conference call will follow the results announcement, allowing investors to engage directly with management. The company highlights its innovative Aquablation therapy and significant clinical evidence.
Read more →PRCTEAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH
The European Association of Urology has upgraded Aquablation therapy to a strong recommendation for treating benign prostatic hyperplasia (BPH). This decision is based on robust clinical evidence demonstrating its effectiveness and safety, particularly for patients wishing to maintain ejaculatory function. The guidelines highlight the therapy's applicability across various prostate anatomies and its endorsement by health technology assessment bodies.
Read more →PRCT▼ -6%on this news
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
PROCEPT BioRobotics has announced the international launch of the HYDROS Robotic System, designed for Aquablation therapy to treat benign prostatic hyperplasia (BPH). This AI-enabled platform enhances surgical precision and personalization, offering durable symptom relief while preserving quality of life. The system is set to expand access to effective treatment options for men suffering from BPH.
Read more →PRCT▼ -15.1%on this news
PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth
PROCEPT BioRobotics hosted its 2026 Investor Day in New York, presenting its long-term growth strategy and financial outlook. The company highlighted the significant market opportunity in treating BPH and the clinical success of its Aquablation therapy. PROCEPT aims to enhance its leadership in BPH, with a focus on patient education and international expansion.
Read more →PRCT▼ -15.1%on this newsshared move
PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
PROCEPT BioRobotics reported its fourth quarter 2025 financial results, highlighting a 12% increase in total revenue year-over-year. The company achieved record procedure volumes but faced a net loss of $29.8 million. Looking ahead, PROCEPT has adjusted its 2026 revenue guidance to $390-$410 million, anticipating a growth rate of 27%-33%. The company is focusing on aligning handpiece sales with procedure volumes to drive sustainable growth.
Read more →PRCTPROCEPT BioRobotics® Announces Updated Dates for 4Q25 Earnings Conference Call and Investor Day
PROCEPT BioRobotics has announced updated dates for its fourth quarter 2025 earnings conference call and Investor Day due to travel disruptions from inclement weather. The earnings report will be released on February 25, 2026, followed by a conference call. The in-person Investor Day is rescheduled for February 26, 2026, at NASDAQ Headquarters in New York City.
Read more →PRCT▼ -5.3%on this news
PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference
PROCEPT BioRobotics will present at the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference in March. The company focuses on advancing urology care through its robotic solutions, including the AQUABEAM and HYDROS systems. Webcasts of the presentations will be available for replay on their website.
Read more →PRCTPROCEPT BioRobotics to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City
PROCEPT BioRobotics Corporation has scheduled its fourth quarter of 2025 earnings report for February 24, 2026, followed by an investor day on February 25, 2026, in New York City. The earnings call will take place after market close, while the in-person investor event at NASDAQ Headquarters will commence in the morning. The company emphasizes its focus on transforming urology through advanced robotic solutions, particularly highlighting the AQUABEAM and HYDROS systems used in BPH treatment. Live webcasts of both events will be available on their website, ensuring accessibility for all interested parties.
Read more →PRCTPROCEPT BioRobotics to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025
PROCEPT BioRobotics will present at the 37th Annual Piper Sandler Healthcare Conference in New York City on December 2, 2025. The management's participation highlights the company's commitment to advancing robotic solutions for urology, particularly in treating benign prostatic hyperplasia (BPH). The conference presentation will be accessible via a live webcast, demonstrating the company's focus on investor relations. PROCEPT BioRobotics is recognized for its innovative AQUABEAM and HYDROS robotic systems which are designed to enhance patient care outcomes.
Read more →PRCT▼ -9.7%on this news
PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance
PROCEPT BioRobotics reported strong financial results for Q3 2025, with total revenue reaching $83.3 million, a 43% increase year-over-year. The company experienced significant growth in U.S. system placements and handpiece sales, reflecting strong demand for its HYDROS Robotic System. Despite a slight increase in net loss, the CEO remains optimistic about the company's growth potential and the adoption of Aquablation therapy.
Read more →PRCTPROCEPT BioRobotics to Report Third Quarter 2025 Financial Results on November 4, 2025
PROCEPT BioRobotics is scheduled to report its third quarter 2025 financial results on November 4, 2025. Following the release, management will host a conference call at 4:30 p.m. Eastern Time to discuss the results. The company continues to focus on advancing urological treatments with its robotic systems, including the innovative AQUABEAM and HYDROS technologies designed for BPH treatment.
Read more →PRCT▼ -5%on this news· ran to -19% by day 3
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
PROCEPT BioRobotics reported strong financial results for Q2 2025, showcasing a 48% year-over-year increase in total revenue, driven primarily by robust demand for its robotic systems and consumables. Increased revenue guidance for the full year now stands at $325.5 million, reflecting a 45% growth expectation. Despite these positive developments, the company recorded a net loss of $19.6 million and a rise in operating expenses. The appointment of Larry Wood as CEO is anticipated to enhance company leadership as they focus on expanding the market share of Aquablation therapy.
Read more →PRCTPROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
PROCEPT BioRobotics has announced the retirement of Dr. Reza Zadno as president and CEO, effective September 1, 2025. Larry L. Wood will take over as the new president and CEO starting September 2, 2025. Under Dr. Zadno's leadership, the company achieved significant growth, particularly in the adoption of Aquablation therapy for BPH treatment. The company is also anticipating a revenue of approximately $79.2 million for the second quarter of 2025.
Read more →PRCTAmbulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy
PROCEPT BioRobotics has successfully completed three procedures in the WATER IV trial for prostate cancer using Aquablation therapy at an Ambulatory Surgery Center. This trial compares the safety and efficacy of Aquablation therapy with radical prostatectomy for localized prostate cancer. The results indicate a promising alternative treatment approach that may enhance patient care and reduce costs.
Read more →PRCTPROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025
PROCEPT BioRobotics Corporation announced it will report its second quarter 2025 financial results on August 6, 2025, after market close. A conference call will follow at 4:30 p.m. Eastern Time, accessible via the company's website. The company aims to enhance BPH treatment with its robotic systems and has substantial clinical evidence backing its therapies.
Read more →PRCTAquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
PROCEPT BioRobotics announced that Aquablation therapy will receive a Category I CPT code effective January 1, 2026, replacing the previous Category III code. This change is expected to enhance the therapy's adoption among surgeons and improve patient access. The proposed payment rate for the new code is approximately $540, slightly higher than TURP's rate. The transition reflects the therapy's clinical value and aims to establish it as the standard of care for BPH.
Read more →PRCTPROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
PROCEPT BioRobotics will participate in four investor conferences in May and June 2025. These events include the Bank of America Health Care Conference and the Jefferies Global Healthcare Conference. The company aims to showcase its advancements in robotic solutions for urology, particularly in treating BPH. Webcasts of the presentations will be available for replay on their website.
Read more →PRCTPROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
PROCEPT BioRobotics announced its participation in the 2025 AUA Annual Meeting, showcasing Aquablation therapy for BPH. The event will feature clinical presentations emphasizing the therapy's long-term outcomes and safety. Attendees can engage in hands-on demonstrations of the HYDROS Robotic System, underscoring PROCEPT's leadership in urologic care.
Read more →PRCT▼ -5.6%on this newsshared move
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
PROCEPT BioRobotics Corporation (PRCT) has reported robust financial results for the first quarter of 2025, with total revenue reaching $69.2 million, a 55% increase from the previous year. The company also raised its revenue guidance for the full year to $323 million, highlighting strong sales momentum amidst increasing demand for its robotic systems, particularly the Hydros™ system. Despite the positive growth, PROCEPT reported a net loss of $24.7 million and a significant increase in operating expenses. The results suggest a strong positioning in the surgical robotics market, although challenges related to operational costs remain.
Read more →PRCT▼ -7.2%on this news
PROCEPT BioRobotics Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
PROCEPT BioRobotics Corporation announced it will host an investor event at the Aria Resort in Las Vegas during the American Urological Association Annual Meeting on April 25, 2025. The event will feature presentations from the company's management team and respected physicians in urology. The aim of the gathering is to discuss advancements in BPH treatment and the company's innovative robotic solutions. A live webcast will also be available for those unable to attend in person.
Read more →PRCTPROCEPT BioRobotics Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada
PROCEPT BioRobotics Corporation has announced an upcoming investor event during the 2025 American Urological Association Annual Meeting scheduled for April 25, 2025, in Las Vegas. Senior management will present insights, alongside clinical perspectives from noted physicians in urology. Additionally, the company plans to report its financial results for the first quarter of 2025 on April 24, 2025, with a corresponding conference call to discuss the implications. This event highlights the company's commitment to engaging with investors regarding its innovative urology technologies, including its Aquablation therapy.
Read more →PRCTPROCEPT BioRobotics Reports Fourth Quarter and Full Year 2024 Results
PROCEPT BioRobotics Corporation reported strong financial results for the fourth quarter and full year of 2024, with total revenues reaching approximately $68.2 million for the quarter and $224.5 million for the year, marking significant year-over-year increases. Key highlights include a 57% revenue growth in Q4 driven by increased U.S. system and handpiece sales, as well as successful sales of robotic systems. However, the company noted a decline in procedure orders due to an acute saline shortage, which could impact future performance. Looking ahead, the company projects continued growth and has provided a revenue guidance of $320 million for 2025.
Read more →PRCTPROCEPT BioRobotics to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference
PROCEPT BioRobotics announced that it will report its fourth quarter 2024 financial results on February 25, 2025, followed by a conference call. Additionally, the management will present at the TD Cowen 45th Annual Healthcare Conference on March 4, 2025, and at the 2025 Leerink Partners Healthcare Conference on March 11, 2025. The company continues to focus on innovative solutions in urology, particularly emphasizing its Aquablation therapy, which has garnered significant clinical support.
Read more →PRCTPROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
PROCEPT BioRobotics, a surgical robotics company, announced its participation in the 36th Annual Piper Sandler Healthcare Conference scheduled for December 4, 2024, in New York City. Management will present at 8:30 a.m. Eastern Time, and details of the presentation will be accessible via a live webcast. The company is recognized for its AI-powered HYDROS Robotic System, designed to deliver Aquablation therapy. PROCEPT BioRobotics continues to build clinical evidence supporting its innovative solutions in urology.
Read more →PRCTPROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock
PROCEPT BioRobotics Corporation has announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock at a price of $91.00 per share, aiming to raise around $175 million. The offering is set to close on or about October 31, 2024, subject to standard conditions. This capital raise reflects the company's focus on advancing its transformative solutions in urology, particularly through its innovative AquaBeam and HYDROS robotic systems. The offering does not include proceeds to PROCEPT from shares sold by a selling stockholder.
Read more →PRCT▲ +32.3%on this newsshared move
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
PROCEPT BioRobotics Corporation has announced a proposed public offering of $175 million in common stock. An additional $26.25 million may be available if underwriters exercise their option. Although the capital raised could support further advancements in urological solutions, the offering's completion is dependent on market conditions and other factors. PROCEPT will not benefit from shares sold by a selling stockholder, highlighting financial limitations and market uncertainties.
Read more →PRCT▲ +32.3%on this newsshared move
PROCEPT BioRobotics Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance
PROCEPT BioRobotics reported a significant increase in third quarter 2024 revenues, which reached $58.4 million, up 66% from the previous year. The company also noted substantial growth in international revenue, rising by 122%. Gross margins hit a record 63.2%, attributed to higher selling prices and improved production efficiencies. Despite this positive performance, the company continues to face challenges, projecting an Adjusted EBITDA loss of $60 million for the year.
Read more →PRCTPROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024
PROCEPT BioRobotics has announced that it will report its financial results for the third quarter of 2024 on October 28, 2024, prior to market opening. The company, which specializes in urological surgical robotics, has scheduled a conference call at 8:00 a.m. Eastern Time to discuss these results. Investors are encouraged to participate via a live webcast or by dialing in. PROCEPT BioRobotics continues to develop transformative solutions that enhance patient care, particularly through its AQUABEAM and HYDROS robotic systems.
Read more →PRCTPROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
PROCEPT BioRobotics has received FDA approval to begin a pivotal randomized clinical study focused on Aquablation therapy for localized prostate cancer. This study, known as WATER IV PCa, will compare the safety and efficacy of Aquablation therapy against traditional radical prostatectomy in up to 280 patients. The trial is designed to provide long-term insights into treatment-related harms and oncologic events, potentially changing the treatment landscape for prostate cancer therapies. Additionally, the company has been granted Breakthrough Device Designation, which may facilitate the therapy's path to market.
Read more →PRCTPROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
PROCEPT BioRobotics, a surgical robotics company, will present at the 2024 Wells Fargo Healthcare Conference on September 4, 2024. The presentation will highlight their innovative solutions in urology, particularly their AI-Powered HydroSTM Robotic System designed for effective Aquablation therapy. This therapy is aimed at treating lower urinary tract symptoms associated with BPH, which affects about 40 million men in the U.S. An archived webcast of the presentation will be available on the company's website after the event.
Read more →PRCT▲ +28.4%on this news
PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation Therapy
PROCEPT BioRobotics has received FDA clearance for its HYDROS Robotic System, an AI-powered platform for Aquablation therapy. This system incorporates advanced technologies such as AI treatment planning and enhanced imaging to improve surgical outcomes. The clearance signifies a pivotal advancement for the company, which already has over 400 robotic systems in the U.S. market. The HYDROS system aims to enhance the efficiency and accuracy of treatments for patients with benign prostatic hyperplasia (BPH), ensuring better clinical results.
Read more →PRCTPROCEPT BioRobotics Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance
PROCEPT BioRobotics reported significant financial growth for Q2 2024, with total revenue reaching $53.4 million, a 61% increase from Q2 2023. The company has also revised its full-year revenue guidance upward to approximately $217 million, reflecting strong performance in the U.S. market, where system and consumables sales saw notable increases. Despite this success, the company reported a slight increase in net loss and higher operating expenses, indicating ongoing challenges as it scales operations.
Read more →PRCTPROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
PROCEPT BioRobotics Corporation announced it will release its financial results for the second quarter of 2024 on August 1, 2024, following the market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results. The company emphasizes its commitment to improving patient care through its innovative AquaBeam Robotic System, which addresses benign prostatic hyperplasia. Clinical evidence suggests that their Aquablation therapy offers various benefits for patients with lower urinary tract symptoms.
Read more →PRCTPROCEPT BioRobotics Announces New CPT Category I Code from the American Medical Association for Aquablation therapy
PROCEPT BioRobotics has announced that the American Medical Association has established a new Category I CPT code for Aquablation therapy, set to take effect on January 1, 2026. This decision was made due to the rising utilization of the therapy and its strong clinical evidence. The new code replaces the existing Category III code and signifies a notable advancement in the reimbursement framework for the procedure, which is designed to treat benign prostatic hyperplasia effectively and safely.
Read more →PRCTPROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
PROCEPT BioRobotics will present at the 2024 Truist Securities MedTech Conference on June 18, 2024, in Boston, Massachusetts. The company aims to highlight its advancements in urological surgery through its AquaBeam Robotic System. This technology focuses on treating benign prostatic hyperplasia (BPH) and is supported by a robust foundation of clinical evidence. The presentation will be accessible via a live webcast and archived for future viewing.
Read more →PRCTPROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
PROCEPT BioRobotics announced its participation in two upcoming conferences, the 2024 Leerink Partners Healthcare Crossroads Conference and the 44th Annual William Blair Growth Stock Conference. Scheduled presentations will offer insights into the company's advancements in surgical robotics, particularly in urology. Notably, the AquaBeam Robotic System, designed for treating benign prostatic hyperplasia, will be highlighted. Webcasts of the presentations will be available for investors to access online after the events.
Read more →PRCT▲ +14.4%on this news
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
PROCEPT BioRobotics Corporation reported its financial results for the first quarter of 2024, revealing a significant 83% increase in total revenue, amounting to $44.5 million. The company also raised its 2024 revenue guidance to $213.5 million, driven by increases in system sales and handpiece revenue. Despite strong revenue growth, the company reported a net loss of $26 million and an uptick in operating expenses due to ongoing investments in its commercial strategy and R&D. Notably, the gross margin improved to 56%, reflecting operational efficiencies and revenue surge.
Read more →PRCT▲ +5%on this news
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
PROCEPT BioRobotics has announced that 12 scientific abstracts concerning its Aquablation therapy for benign prostatic hyperplasia will be presented at the 2024 AUA Annual Meeting in San Antonio, Texas. The therapy is recognized for delivering durable symptom relief while maintaining sexual function across various prostate sizes. The presentations aim to showcase the growing body of clinical evidence supporting Aquablation's efficacy. Additionally, the company will conduct hands-on workshops and engage with conference attendees, emphasizing its commitment to advancing urological care.
Read more →PRCTPROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
PROCEPT BioRobotics Corp. will host an investor event during the 2024 AUA Annual Meeting in San Antonio, Texas, on May 3, 2024. The event will feature presentations from key management members and clinical perspectives from notable physicians in urology. Additionally, a live webcast of the event will be available for those unable to attend in person. The company continues to promote its AquaBeam Robotic System, aimed at providing effective solutions for benign prostatic hyperplasia (BPH).
Read more →PRCTPROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced the date for its first quarter 2024 financial results, set for May 1, 2024, accompanied by a conference call for investors. Additionally, the company will participate in the 2024 Bank of America Healthcare Conference on May 15, 2024. Through these events, PROCEPT aims to inform stakeholders about its business performance and future initiatives. The company continues to advance its AquaBeam Robotic System, which targets benign prostatic hyperplasia in males.
Read more →PRCTPROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
PROCEPT BioRobotics reported its financial results for the fourth quarter and full year 2023, showcasing substantial revenue growth of 83% in Q4, totaling approximately $43.6 million. The company also provided positive revenue guidance for 2024, projecting around $210 million, which indicates a continued upward trend. However, PROCEPT reported a net loss of $27.5 million for Q4 due to increased operating expenses and ongoing investment in commercial expansion. Despite these challenges, management expressed confidence in establishing AquaBeam as a leading solution in urology.
Read more →PRCTPROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
PROCEPT BioRobotics announced its participation at the 44th Annual TD Cowen Health Care Conference in Boston, where management will present on March 5. The presentation is expected to discuss their innovative AquaBeam Robotic System, aimed at improving patient care in urology, particularly for benign prostatic hyperplasia (BPH). The company emphasizes its commitment to advancing surgical techniques through well-supported clinical evidence. The event will include a live webcast available for replay afterward.
Read more →PRCTPROCEPT BioRobotics Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
PROCEPT BioRobotics Corporation has announced its preliminary revenue figures for the fourth quarter of 2023, projecting revenues between $43.3 million and $43.6 million, a significant increase from $23.8 million year-over-year. The company expects fiscal year 2023 revenues to be around $135.9 million to $136.2 million, reflecting robust growth driven by system sales and utilization of their Aquablation Therapy. CEO Reza Zadno expressed optimism about the company's trajectory entering 2024, citing strong interest from surgeons and historic sales performance. Full financial details will be reported on February 27, 2024.
Read more →PRCTPROCEPT BioRobotics Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
PROCEPT BioRobotics has reported strong financial results for the third quarter of 2023, achieving a total revenue of $35.1 million, representing a 72% increase compared to the same quarter in 2022. The company also raised its revenue guidance for the full year to approximately $133.5 million. Significant achievements include a successful equity follow-on offering that raised around $162 million and obtaining FDA IDE approval to investigate Aquablation Therapy for prostate cancer. Despite a net loss of $24.6 million for the quarter, the overall outlook remains positive as the demand for their solutions grows.
Read more →PRCT▲ +9.6%on this news
PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023
PROCEPT BioRobotics Corporation announced that it will report its financial results for the third quarter of 2023 after market close on November 1, 2023. A conference call will follow at 4:30 p.m. Eastern Time to discuss these results. The company is known for its AquaBeam Robotic System, which offers novel therapies for treating benign prostatic hyperplasia (BPH), a common prostate condition affecting many men in the U.S.
Read more →PRCTPROCEPT BioRobotics Announces New Corporate Headquarters in San Jose
PROCEPT BioRobotics has officially opened its new corporate headquarters in San Jose, California, aiming to support the company's growth and innovation in surgical robotics. The facility will help the company attract talent and enhance its operational capabilities. CEO Reza Zadno highlighted the increasing demand for their Aquablation therapy as a key reason for the move, underlining the importance of Silicon Valley's rich talent pool in their strategic decision.
Read more →PRCTPROCEPT BioRobotics Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation Therapy for Prostate Cancer
PROCEPT BioRobotics has obtained Investigational Device Exemption approval from the U.S. FDA to investigate the safety and efficacy of its Aquablation therapy for prostate cancer. The approval enables the company to initiate a single-arm feasibility study at three renowned cancer centers. Aquablation therapy leverages a unique waterjet resection technique, which may provide an effective treatment option while preserving patient quality of life. This development is significant for PROCEPT as it aims to expand its treatment offerings beyond benign prostatic hyperplasia.
Read more →PRCTPROCEPT BioRobotics Announces First Commercial Aquablation Therapy Procedures in Japan
PROCEPT BioRobotics has completed its first commercial Aquablation therapy procedures in Japan at two prominent medical institutions. This marks a significant milestone in the company's global expansion and reflects a growing acceptance of Aquablation as a treatment for benign prostatic hyperplasia (BPH). Notable Japanese urologists have praised the technology for its precision and effectiveness, suggesting it sets a new standard in prostate treatment. The company plans to leverage strong clinical data and support from key opinion leaders to enhance adoption in the Japanese market.
Read more →PRCTPROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston
PROCEPT BioRobotics, a company specializing in surgical robotics for urology, has announced that its management will present at the 2023 Wells Fargo Healthcare Conference in Boston on September 7. The presentation will showcase the company's advancements, particularly its AquaBeam Robotic System used for treating benign prostatic hyperplasia (BPH). This event underscores the company's ongoing efforts to engage with investors and highlight the clinical benefits of its innovative therapy.
Read more →PRCT▲ +6.1%on this news
PROCEPT BioRobotics Corporation Announces Pricing of Upsized Offering of Common Stock
PROCEPT BioRobotics Corporation has announced the pricing of an upsized public offering of 4,422,169 shares at $33.92 per share, aiming for approximately $150 million in gross proceeds. The offering includes an option for underwriters to purchase an additional 663,325 shares. This move comes as the company continues to grow its revolutionary AquaBeam Robotic System designed for minimally invasive urologic surgery. The offering is expected to close on or about August 4, 2023, subject to customary closing conditions.
Read more →PRCT▼ -7.1%on this newsshared move
PROCEPT BioRobotics Reports Second Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
PROCEPT BioRobotics Corporation reported significant financial results for the second quarter of 2023, achieving a 98% increase in total revenue year-over-year, totaling $33.1 million. The company sold a record 40 robotic systems during this quarter and has raised its revenue guidance for 2023 to approximately $131 million. Despite these positive developments, the company's net loss widened to $25.3 million, influenced by increased operating expenses. Looking forward, PROCEPT remains optimistic about its growth prospects, backed by improved coverage policies and a strong pipeline of opportunities.
Read more →PRCT▼ -6.4%on this news
PROCEPT BioRobotics to Report Second Quarter 2023 Financial Results on July 27, 2023
PROCEPT BioRobotics Corporation announced it will report its second quarter financial results on July 27, 2023, before market open. The company specializes in surgical robotics, particularly for urology, and will hold a conference call at 8:00 a.m. Eastern Time to discuss these results. Investors can access the conference call via webcast or through dial-in registration. The company continues to advance its AquaBeam Robotic System designed for minimally invasive urologic surgery, especially for benign prostatic hyperplasia (BPH).
Read more →PRCT▲ +13.8%on this news
PROCEPT BioRobotics Corporation: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm has announced an investigation into PROCEPT BioRobotics Corporation regarding potential securities fraud. This initiative follows concerns that the company may have made untrue or misleading statements, affecting investor trust. Investors who suffered losses are encouraged to contact the law firm for a complimentary case evaluation. A class action lawsuit may be filed depending on the findings of the investigation.
Read more →PRCT▼ -25.3%on this newsshared move
PROCEPT BioRobotics Reports First Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
PROCEPT BioRobotics Corporation reported significant financial results for the first quarter of 2023, showcasing a 72% increase in total revenue, amounting to $24.4 million. The company also raised its revenue guidance for the fiscal year to $128 million, reflecting robust growth in U.S. handpiece sales and consumables. However, the company reported a net loss of $28.5 million, which is an increase from the previous year's loss. Operational expenses also surged, which may raise concerns for investors even amid positive revenue trajectories.
Read more →PRCTPROCEPT BioRobotics to Report First Quarter 2023 Financial Results on April 27, 2023 and Present at the Bank of America 2023 Health Care Conference in Las Vegas
PROCEPT BioRobotics Corporation announced it will release its financial results for the first quarter of 2023 before market open on April 27, 2023. A conference call will follow on the same day at 8:00 a.m. Eastern Time. Additionally, the company's management is scheduled to present at the Bank of America 2023 Health Care Conference in Las Vegas on May 10, 2023. The company focuses on developing transformative robotic solutions for urology, particularly the AquaBeam Robotic System for treating benign prostatic hyperplasia.
Read more →PRCT▲ +11.5%on this newsshared move
PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates
PROCEPT BioRobotics Corporation announced that United Healthcare will cover Aquablation therapy for men with lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH). This decision, effective June 1, 2023, aligns with the therapy's FDA indications and improves access for an estimated 95% of men in the U.S. The therapy is notable for its robotic approach aimed at minimizing side effects while maintaining effective treatment outcomes. The announcement underscores the growing adoption and recognition of Aquablation therapy in the healthcare landscape.
Read more →PRCTPROCEPT BioRobotics Corp. Announces Investor Event at 2023 AUA Annual Meeting in Chicago
PROCEPT BioRobotics Corporation announced an investor event scheduled for April 28, 2023, at the American Urological Association Annual Meeting in Chicago. The event will feature presentations from the company's executive team and a surgeon panel discussing the benefits of Aquablation therapy. A live webcast will make the event accessible for those unable to attend in person, with recordings available for 90 days post-event. The company emphasizes its focus on advancing patient care through innovative surgical solutions in urology, particularly for benign prostatic hyperplasia (BPH).
Read more →PRCT▼ -8.5%on this news
PROCEPT BioRobotics Corp. to Present at the Virtual Key Bank Life Sciences & MedTech Investor Forum
PROCEPT BioRobotics Corporation will present at the Virtual Key Bank Life Sciences & MedTech Investor Forum on March 21, 2023. Management aims to communicate their advances in urology and highlight their AquaBeam Robotic System, which addresses benign prostatic hyperplasia. The event will include a live webcast available for 90 days, ensuring broad accessibility. The company emphasizes its commitment to enhancing patient care through innovative robotic solutions.
Read more →PRCTPROCEPT BioRobotics Reports Fourth Quarter and Full Year 2022 Results
PROCEPT BioRobotics Corporation reported robust financial results for the fourth quarter and full year of 2022, showcasing significant growth with total revenue up 118% year-over-year. In Q4 2022 alone, revenue reached $23.8 million, a 135% increase compared to the same quarter last year. The company anticipates continued growth into 2023, projecting total revenue of approximately $125 million. However, the company faced challenges, including a higher net loss and increased operating expenses attributed to expansion efforts.
Read more →PRCTPROCEPT BioRobotics Corp. to Present at the 43rd Annual Cowen Health Care Conference in Boston
PROCEPT BioRobotics Corporation will present at the 43rd Annual Cowen Health Care Conference in Boston on March 7. The company focuses on developing advanced surgical robotics solutions in urology, specifically through its AquaBeam Robotic System. The presentation will be live-streamed and available for later viewing. PROCEPT's Aquablation therapy offers effective treatment for men suffering from benign prostatic hyperplasia (BPH), supported by substantial clinical evidence.
Read more →PRCT▼ -6.2%on this news
PROCEPT BioRobotics Announces Preliminary Fourth Quarter and Fiscal Year 2022 Revenue
PROCEPT BioRobotics Corporation reported preliminary revenue estimates for the fourth quarter and fiscal year 2022. The company's Q4 revenue is expected to range from $23.6 million to $23.8 million, marking a substantial increase from $10.1 million in the same period last year. Additionally, FY 2022 revenue is projected to reach approximately $74.8 million to $75.0 million, representing about 117% growth year-over-year. The final financial results will be disclosed on February 28, 2023, accompanied by a conference call for shareholders.
Read more →PRCT▼ -5.2%on this news
PROCEPT BioRobotics Corp. to Present at the 41st Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the
Read more →PRCTPROCEPT BioRobotics Reports Third Quarter 2022 Financial Results and Increases 2022 Revenue Guidance
REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for
Read more →PRCTPROCEPT BioRobotics to Report Third Quarter 2022 Financial Results on November 3, 2022
REDWOOD CITY, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial resul
Read more →PRCTPROCEPT BioRobotics Announces $52 Million Debt Refinancing
REDWOOD CITY, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that it has entered into a new
Read more →PRCTPROCEPT BioRobotics Corp. to Present at 2022 Wells Fargo Healthcare Conference
REDWOOD CITY, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present and ho
Read more →PRCTPROCEPT BioRobotics Reports Second Quarter 2022 Financial Results and Increases 2022 Revenue Guidance
REDWOOD CITY, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for
Read more →PRCTPROCEPT BioRobotics to Report Second Quarter 2022 Financial Results on August 4, 2022
REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the secon
Read more →PRCTPROCEPT BioRobotics Corporation Announces Additional Positive Coverage Policies Regarding Aquablation Therapy for Men with Enlarged Prostates
REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that five new regional private insurance plans
Read more →PRCT▼ -5.6%on this news· ran to -18% by day 3
PROCEPT BioRobotics Reports First Quarter 2022 Financial Results and Increases 2022 Revenue Guidance
REDWOOD CITY, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for
Read more →PRCT▲ +5.8%on this news
PROCEPT BioRobotics Corporation Announces Aetna and Independence Blue Cross Blue Shield Positive Coverage Decisions Regarding Aquablation Therapy for Men with Enlarged Prostates
REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that Aetna US Healthcare published an update
Read more →PRCTPROCEPT BioRobotics Corp. to Report First Quarter 2022 Financial Results on May 5, 2022 and attend the 2022 Bank of America Healthcare Conference on May 11, 2022
REDWOOD CITY, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the firs
Read more →PRCTPROCEPT BioRobotics Corp. Announces Investor Event at 2022 AUA Annual Meeting in New Orleans
REDWOOD CITY, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on F
Read more →PRCT▲ +6.2%on this news
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2021 Financial Results
REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter a
Read more →PRCTPROCEPT BioRobotics Corp. to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report finical results for the fourth
Read more →PRCTPROCEPT Announces 5-Year WATER Study Data Comparing Aquablation to TURP
– Symptom reduction and uroflow improvement proved durable and consistent compared to TURP – Larger prostates (≥50 ml) demonstrated a larger safety and efficacy benefit for Aquablation over TURP – 5-year Aquablation retreatment rate was 51% less compared to TURP REDWOOD CITY,
Read more →PRCTPROCEPT BioRobotics Corp. to Present at 11th Annual SVB Leerink Global Healthcare Conference and Cowen’s 42nd Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present virtua
Read more →PRCTPROCEPT BioRobotics Corp. Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
REDWOOD CITY, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the fourth qu
Read more →PRCTPROCEPT BioRobotics Appoints Mary Garrett to Board of Directors
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Mary Garrett to its Board o
Read more →PRCTPROCEPT BioRobotics Corp. Reports Third Quarter 2021 Financial Results and Provides 2021 Revenue Guidance
REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the quarter ended Septem
Read more →PRCTPROCEPT BioRobotics Appoints Elisabeth Sandoval to Board of Directors
REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Elisabeth Sandoval to its B
Read more →PRCTPROCEPT BioRobotics Corp. to Report Third Quarter 2021 Financial Results on November 4, 2021
REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third
Read more →PRCTPROCEPT BioRobotics Corporation Announces Cigna Adds Aquablation Therapy to its Coverage Policy
REDWOOD CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced a new positive coverage decision from Cigna,
Read more →PRCTPROCEPT BioRobotics Corporation Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
REDWOOD CITY, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (“PROCEPT”), a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the closing of it
Read more →PRCTPROCEPT BioRobotics Corporation Announces Pricing of Upsized Initial Public Offering
REDWOOD CITY, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (“PROCEPT”), a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of it
Read more →Competitive Position
How PRCT ranks across every disease it competes inCompetitive Position is a premium feature
See how PRCT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial